- ►diabetesjournals.org S Han, DL Hagan, JR Taylor, L Xin, W Meng, … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—Dapagliflozin potently and selectively inhibited human SGLT2 versus
human SGLT1, the major cotransporter of glucose in the gut, and did not
significantly inhibit facilitative glucose transport in human adipocytes. ... Cited by 26 - Related articles - All 5 versions
W Meng, BA Ellsworth, AA Nirschl, PJ McCann … - Journal of medicinal chemistry, 2008 - ncbi.nlm.nih.gov The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective
hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner
by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These ... Cited by 21 - Related articles - All 4 versions
- ►aspetjournals.org K Katsuno, Y Fujimori, Y Takemura, M Hiratochi … - Journal of Pharmacology and Experimental …, 2007 - ASPET The low-affinity sodium glucose cotransporter (SGLT2), which is expressed
specifically in the kidney, plays a major role in renal glucose reabsorption in
the proximal tubule. We have discovered sergliflozin, a prodrug of a novel ... Cited by 31 - Related articles - All 5 versions
B Komoroski, N Vachharajani, Y Feng, L Li, D … - Clinical Pharmacology & Therapeutics, 2009 - nature.com Dapagliflozin, administered to patients in once-daily oral doses, is a
sodium–glucose cotransporter 2 (SGLT2) inhibitor that blocks the reabsorption
of glucose from urine into the blood. This 14-day study randomized patients ... Cited by 11 - Related articles - All 4 versions
B Komoroski, N Vachharajani, D Boulton, D … - Clinical Pharmacology & Therapeutics, 2009 - nature.com Dapagliflozin selectively inhibits renal glucose reabsorption by inhibiting
sodium–glucose cotransporter-2 (SGLT2). It was developed as an
insulin-independent treatment approach for type 2 diabetes mellitus (T2DM). ... Cited by 6 - Related articles - All 4 versions
[CITATION] Dapagliflozin (BMS-512148), a selective inhibitor of the sodium-glucose uptake transporter …
B Komoroski, E Brenner, L Li, N Vachharajani … - DIABETES-NEW YORK-SUPPLEMENT-, 2007 - American Diabetes Association; 1999 Cited by 7 - Related articles - BL Direct
J Calado, J Loeffler, O Sakallioglu, F Gok, K … - Kidney International, 2006 - nature.com Familial renal glucosuria (FRG) is an inherited renal tubular disorder
characterized by persistent isolated glucosuria in the absence of hyperglycemia.
Mutations in the sodium/glucose co-transporter SGLT2 coding gene, SLC5A2, ... Cited by 19 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org JF List, V Woo, E Morales, W Tang, FT … - Diabetes Care, 2009 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS Type 2 diabetic patients were randomly assigned to
one of five dapagliflozin doses, metformin XR, or placebo for 12 weeks. The
primary objective was to compare mean change from baseline in A1C. Other ... Cited by 13 - Related articles - All 3 versions
MA Abdul-Ghani, RA DeFronzo - Endocrine Practice, 2008 - AACE The prevalence of type 2 diabetes mellitus (T2DM) has increased progressively to
epidemic proportions dur- ing the past 20 years (1). Patients with T2DM have
increased morbidity and mortality, the majority of which results from ... Cited by 5 - Related articles - All 2 versions
AL Handlon - Expert Opin. Ther. Patents, 2005 - Informa Pharma Science Sodium glucose co-transporter 2 (SGLT2) plays a key role in maintaining glu-
cose equilibrium in the human body. SGLT2 is a kidney transporter that reab-
sorbs glucose from the renal filtrate and prevents the loss of glucose in ... Cited by 11 - Related articles - BL Direct - All 4 versions
